Last reviewed · How we verify
Anti-integrin - Vedolizumab IV
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on immune cells, preventing their migration to the gut and reducing intestinal inflammation.
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on immune cells, preventing their migration to the gut and reducing intestinal inflammation. Used for Moderate to severe ulcerative colitis, Moderate to severe Crohn's disease.
At a glance
| Generic name | Anti-integrin - Vedolizumab IV |
|---|---|
| Sponsor | University of Calgary |
| Drug class | Anti-integrin monoclonal antibody |
| Target | α4β7 integrin |
| Modality | Biologic |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Vedolizumab binds to α4β7 integrin, an adhesion molecule expressed on gut-homing lymphocytes, and prevents these cells from adhering to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the intestinal vasculature. This selective gut-targeting mechanism reduces immune cell infiltration into the bowel while sparing systemic immunity, thereby decreasing intestinal inflammation in inflammatory bowel disease.
Approved indications
- Moderate to severe ulcerative colitis
- Moderate to severe Crohn's disease
Common side effects
- Nasopharyngitis
- Headache
- Arthralgia
- Nausea
- Pyrexia
- Infections (serious)
Key clinical trials
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (PHASE1, PHASE2)
- Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning (PHASE2)
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (PHASE4)
- Vedolizumab Post Op Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-integrin - Vedolizumab IV CI brief — competitive landscape report
- Anti-integrin - Vedolizumab IV updates RSS · CI watch RSS
- University of Calgary portfolio CI